Detailed Information on Publication Record
2004
Prognostic factors of the Pharynx and supraglottic Carcinoma
KOSTŘICA, Rom, Pavel SMILEK, Jan ROTTENBERG, Karel VESELÝ, Ladislav DUŠEK et. al.Basic information
Original name
Prognostic factors of the Pharynx and supraglottic Carcinoma
Name (in English)
Prognostic factors of the Pharynx and supraglottic Carcinoma
Authors
KOSTŘICA, Rom (203 Czech Republic), Pavel SMILEK (203 Czech Republic, guarantor), Jan ROTTENBERG (203 Czech Republic), Karel VESELÝ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and Jiří HLOŽEK (203 Czech Republic)
Edition
Stuttgart, HNO Infromationen, p. 139-139, 2004
Publisher
Karl Demetr Verlag im Georg Thieme VErlag
Other information
Language
Czech
Type of outcome
Stať ve sborníku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Canada
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/04:00010082
Organization unit
Faculty of Medicine
ISBN
03 44-93 19
Keywords in English
Prognosis of head and neck carcinoma - DNA content - Ki-67
Změněno: 2/6/2004 08:02, doc. MUDr. Pavel Smilek, Ph.D.
V originále
The analysis was carried out with a set of 60 patients suffering from carcinoma of the pharynx and supraglottis treated at the Clinic of Otorhinolaryngology and Head and Neck Surgery in Brno within 1991 - 1999. Besides routine examinations, flow cytometric analysis of DNA was performed and Ki-67 marker was established by means of immunohistochemistry. The evaluation of kinetic parameters of the cellular cycle has revealed quite clearly the significantly lower share of SPF in tumors with poor prognosis. Tumors with direct progression immediately after treatment have shown statistically significantly higher share of cells in G2/M phase.
In English
The analysis was carried out with a set of 60 patients suffering from carcinoma of the pharynx and supraglottis treated at the Clinic of Otorhinolaryngology and Head and Neck Surgery in Brno within 1991 - 1999. Besides routine examinations, flow cytometric analysis of DNA was performed and Ki-67 marker was established by means of immunohistochemistry. The evaluation of kinetic parameters of the cellular cycle has revealed quite clearly the significantly lower share of SPF in tumors with poor prognosis. Tumors with direct progression immediately after treatment have shown statistically significantly higher share of cells in G2/M phase.
Links
| MSM 141100003, plan (intention) |
|